Results 61 to 70 of about 25,067 (205)

NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy

Cell Death and Disease
Olaparib has been approved as a therapeutic option for metastatic pancreatic ductal adenocarcinoma patients with BRCA1/2 mutations. However, a significant majority of pancreatic cancer patients have inherent resistance or develop tolerance to olaparib ...
Mingming Xiao, Jing Yang, Mingwei Dong, Xiaoqi Mao, Haoqi Pan, Yalan Lei, Xuhui Tong, Xiaoning Yu, Xianjun Yu, Si Shi   +9 more
doaj   +1 more source

PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-кB pathway activity and DNA damage response induced by Idarubicin

Acta Biochimica et Biophysica Sinica, 2021
Idarubicin (IDA), an anthracycline antineoplastic drug, is commonly used in the treatment of acute myeloid leukemia (AML) with reasonable response rates and clinical benefits.
Ke Bo, Li Anna, Fu Huan, Kong Chunfang, Liu Tingting, Zhu Qingqing, Zhang Yue, Zhang Zixia, Chen Chen, Jin Chenghao   +9 more
doaj   +1 more source

Membrane Fusion‐Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng, Tristan Juin Han Chang, Xinchao Li, Zhongqi Zhou, Chung Tin, Kenward Vong, Pierre Karam, Pik Kwan Lo   +7 more
wiley   +1 more source

PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis

European Urology Open Science
Background and objective: Olaparib is one of the earliest approved treatment options for metastatic castration-resistant prostate cancer (mCRPC). This systematic review and network meta-analysis aimed to determine the optimal olaparib strategy for ...
Yixian Li, Zongyu Li, Hongxia Lu, Pengjie Shi, Yiting Liu, Lilong Liu, Ke Chen   +6 more
doaj   +1 more source

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation

Cancer Medicine, 2018
Cholangiocarcinoma (CCA) is a highly malignant tumor with resistance to radiotherapy alone. Olaparib, a highly potent poly(ADP‐ribose) polymerase (PARP) inhibitor, has been shown to sensitize many types of tumor to radiotherapy.
Yize Mao, Xin Huang, Zeyu Shuang, Guohe Lin, Jun Wang, Fangting Duan, Jianlin Chen, Shengping Li   +7 more
doaj   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Olaparib increases the SCE frequency in repair-proficient human cells.

, 2016
A. Cells were exposed with BrdU and 1μM olaparib during two cell cycle periods. Representatives of two metaphase spreads harvested from untreated (left) and olaparib treated (right) primary T cells 2. Arrows, e.g. site of SCE. B. Spontaneous and olaparib-
Shuhei Ito (3151281), Mary Ellen Moynahan (111580), Maria Jasin (47165), Conleth G. Murphy (3151284), Ekaterina Doubrovina (3151287)   +4 more
core   +1 more source

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2^MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors

Cells
Resistance to olaparib is the major obstacle in targeted therapy for ovarian cancer (OC) with poly(ADP-ribose) polymerase inhibitors (PARPis), prompting studies on novel combination therapies to enhance olaparib efficacy.
Łukasz Biegała, Damian Kołat, Arkadiusz Gajek, Elżbieta Płuciennik, Agnieszka Marczak, Agnieszka Śliwińska, Michał Mikula, Aneta Rogalska   +7 more
doaj   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer [PDF]

, 2020
BACKGROUND: We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had ...
Shore, Neal, PROfound Trial Investigators, Corcoran, C, Shore, N, Mateo, J, Fizazi, K, Sandhu, S., Fizazi, K., Roubaud, G., Sandhu, S, Roubaud, Guilhem, Kang, Jinyu, Saad, F, Olmos, David, Twardowski, P., Sartor, Oliver, Gresty, Christopher, Mehra, N., Hussain, M., Mateo, Joaquin, Özgüroğlu, M, Burgents, Joseph, Sartor, O, Olmos, D., Sandhu, Shahneen, Fizazi, Karim, Saad, Fred, de Bono, Johann, Adelman, Carrie A, Corcoran, Claire, Roubaud, G, Adelman, CA, Olmos, D, Gresty, C., Thiery-Vuillemin, Antoine, Thiery-Vuillemin, A, Özgüroğlu, Mustafa, Gresty, C, Burgents, J, Thiery-Vuillemin, A., Twardowski, P, Hussain, Maha, Chi, Kim N, Mateo, J., Burgents, J., Shore, N., Chi, KN, Özgüroğlu, M., Agarwal, N, de Bono, J, Chi, K.N., Sartor, O., Adelman, Caroline, Hussain, M, Agarwal, Neeraj, Twardowski, Przemyslaw, Corcoran, C., Kang, J., Kang, J, Saad, F., Bono, J. de, PROfound Trial Investigators,, Agarwal, N.   +62 more
core   +1 more source